Predicting the outcome of prostate biopsy: comparison of a novel logistic regression‐based model, the prostate cancer risk calculator, and prostate‐specific antigen level alone

Abstract

ROC analyses show that the PCPT risk calculator modestly improves the performance of PSA level alone in predicting an individual's risk of prostate cancer or high-grade disease on biopsy. This predictive tool might be enhanced by including percentage free PSA and the number of biopsy cores.